Viatris (VTRS) Profit After Tax (QoQ) (2020 - 2026)
Viatris (VTRS) Profit After Tax (QoQ) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.64 Bn | 87.78 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.90 Bn | 32.16 Bn | 1.97 Bn |
| 3 | Zoetis | 32.50 Bn | 30.56 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.98 Bn | 20.83 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.38 Bn | 18.57 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.46 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.67 Bn | 12.24 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 151.87% |
| Dec 31, 2025 | -165.29% |
| Sep 30, 2025 | -2,686.96% |
| Jun 30, 2025 | 99.85% |
| Mar 31, 2025 | -488.96% |
| Dec 31, 2024 | -644.83% |
| Sep 30, 2024 | 129.04% |
| Jun 30, 2024 | -386.57% |
| Mar 31, 2024 | 114.88% |
| Dec 31, 2023 | -330.88% |
| Sep 30, 2023 | 25.61% |
| Jun 30, 2023 | 17.49% |
| Mar 31, 2023 | -77.78% |
| Dec 31, 2022 | 185.41% |
| Sep 30, 2022 | 12.87% |
| Jun 30, 2022 | -21.37% |
| Mar 31, 2022 | 251.33% |
| Dec 31, 2021 | -184.69% |
| Sep 30, 2021 | 211.57% |
| Jun 30, 2021 | 73.09% |